Ligandal develops effective antidote to SARS-CoV-2
(WorldNews Health)

Ligandal, one of the world`s most innovative genetic medicine companies, today announces the positive results of laboratory studies that demonstrate the effectiveness of its synthetic peptide, SARS-BLOCK™, as a combination treatment and vaccine to COVID-19. The experiments, in conjunction with the Stroud Lab, University of California San Francisco, demonstrate SARS-BLOCK™halts infection of SARS-CoV-2. In addition...